Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of cancer antigen 15-3 with distant recurrence in immunohistochemically defined breast cancer subtypes in Canadian Cancer Trials Group MA.32.

JNCI cancer spectrum·2026
Same author

Risk of Aortic Root Rupture in Bicuspid Aortic Stenosis: The ABC Sizing Algorithm for SAPIEN 3 Valves.

Circulation. Cardiovascular interventions·2026
Same author

Reply to Vallée M, Stangl FP, Wagenlehner F et al's Letter to the Editor re: Tikkinen KAO, Najafabadi BT, Hajebrahimi S, et al. A Multicenter Randomized Controlled Trial of Antimicrobial Prophylaxis to Prevent Urinary Tract Infections After Shockwave Lithotripsy for Urolithiasis: The APPEAL Trial. Eur Urol 2025;88(6):543-51.

European urology·2026
Same author

Elective neck dissection and adjuvant therapy in N0 major salivary gland cancer: An analysis of the SEER cancer database.

Oral oncology·2026
Same author

The impact of walking on creative thinking: A systematic review and meta-analysis.

PloS one·2026
Same author

Exploration of BMI and circulating metabolic factors as predictors of metformin benefit in CCTG MA.32.

JNCI cancer spectrum·2026

Related Experiment Video

Updated: Apr 19, 2026

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
08:17

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

16.3K

Stereotactic Versus Conventional Radiotherapy in Medically Inoperable Stage I Non-Small Cell Lung Cancer: A Bayesian

Yanchen Wang1, Elysia K Donovan2, Mark N Levine3

  • 1Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada.

Clinical Lung Cancer
|April 17, 2026
PubMed
Summary

Bayesian analysis of the LUSTRE trial suggests stereotactic radiotherapy offers a probable local control benefit for early-stage non-small cell lung cancer patients. Further investigation confirms potential advantages over conventional radiotherapy.

Keywords:
Local controlNSCLCOverall survivalRCTSBRT

More Related Videos

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

15.2K
Stereotactic Radiosurgery for Gynecologic Cancer
10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

18.9K

Related Experiment Videos

Last Updated: Apr 19, 2026

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
08:17

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

16.3K
Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

15.2K
Stereotactic Radiosurgery for Gynecologic Cancer
10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

18.9K

Area of Science:

  • Oncology
  • Radiotherapy
  • Biostatistics

Background:

  • The LUSTRE trial investigated stereotactic body radiotherapy (SBRT) versus conventional radiotherapy (CRT) for early-stage non-small cell lung cancer (NSCLC).
  • Initial trial results were inconclusive, necessitating further analysis.
  • Bayesian methods can integrate prior knowledge to refine inconclusive findings.

Purpose of the Study:

  • To reanalyze the LUSTRE trial data using Bayesian methods.
  • To determine the probability of local control benefit for SBRT in medically inoperable Stage I NSCLC.
  • To assess the impact of different prior distributions on the treatment effect estimate.

Main Methods:

  • The LUSTRE trial randomized 233 patients with medically inoperable Stage I NSCLC 2:1 to SBRT or CRT.
  • Primary outcome was time-to-local control.
  • Bayesian multivariable Cox regression was employed, with sensitivity analyses using neutral, optimistic, and pessimistic prior distributions.

Main Results:

  • With a neutral prior, there was a 91% probability that SBRT improved local control (aHR: 0.63).
  • An optimistic prior yielded a 97% probability of benefit (aHR: 0.62).
  • A pessimistic prior suggested a 57% probability of benefit (aHR: 0.97).

Conclusions:

  • Post hoc Bayesian reanalysis provided valuable insights into the local control probability with SBRT.
  • The findings suggest a potential benefit of SBRT over CRT for early-stage NSCLC, particularly when considering prior evidence.